Visish M Srinivasan1, Adam A Dmytriw2, Robert W Regenhardt3, Juan Vicenty-Padilla2, Naif M Alotaibi3, Elad Levy4, Muhammad Waqas4, Jacob Cherian5, Jeremiah N Johnson6, Pascal Jabbour7, Ahmad Sweid7, Bradley Gross8, Robert M Starke9, Ajit Puri10, Francesco Massari10, Christoph J Griessenauer11,12, Joshua S Catapano1, Caleb Rutledge1, Omar Tanweer6, Parham Yashar13, Gustavo M Cortez14, Mohammad A Aziz-Sultan15, Aman B Patel3, Andrew F Ducruet1, Felipe C Albuquerque1, Ricardo A Hanel14, Michael T Lawton1, Peter Kan16. 1. Department of Neurosurgery, Barrow Neurological Institute, Phoenix, Arizona, USA. 2. Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. NeuroInterventional Program, Massachusetts General Hospital, Boston, Massachusetts, USA. 4. Department of Neurological Surgery, Jacobs School of Medicine at Biomedical Sciences, Buffalo, New York, USA. 5. Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. 6. Department of Neurosurgery, Baylor College of Medicine, Houston, Texas, USA. 7. Department of Neurosurgery, Thomas Jefferson University and Jefferson Hospital for Neuroscience, Philadelphia, Pennsylvania, USA. 8. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 9. Department of Neurosurgery, University of Miami, Miami, Florida, USA. 10. Department of Radiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA. 11. Department of Neurosurgery, Geisinger, Danville, Pennsylvania, USA. 12. Department of Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria, USA. 13. Yashar Neurosurgery, Los Angeles, California, USA. 14. Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA. 15. Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. 16. Department of Neurosurgery, University of Texas Medical Branch, Galveston, Texas, USA.
Abstract
BACKGROUND: The Woven EndoBridge (WEB) device (Terumno Corp. [parent company of Microvention]) was approved by the U.S. Food and Drug Administration as the first intrasaccular device for intracranial aneurysm treatment in December 2018. Its use has become more common since then, but both trial results and postmarket experiences have raised questions about the efficacy in achieving complete aneurysm obliteration. Retreatment after WEB embolization has not been extensively discussed. OBJECTIVE: To discuss the incidence and retreatment of aneurysms after initial WEB embolization. METHODS: Retrospective review across 13 institutions identified all occurrences of WEB retreatment within neurovascular databases. Details regarding demographics, aneurysm characteristics, treatment considerations, clinical outcomes, and aneurysm occlusion were obtained and analyzed. RESULTS: Thirty aneurysms were retreated in 30 patients in a cohort of 342 WEB-treated aneurysms. The retreatment rate was 8.8%. Endovascular methods were used for 23 cases, and 7 were treated surgically. Two aneurysms presented with rehemorrhage after initial WEB embolization. Endovascular treatments included stent-assisted coiling (12), flow diversion (7), coiling (2), PulseRider (Johnson & Johnson)-assisted coiling (1), and additional WEB placement (1). Surgical treatments included primary clipping (6) and Hunterian ligation (1). There were no major complications within the study group. CONCLUSION: WEB retreatments were successfully performed by a variety of techniques, including stent-assisted coiling, clipping, and flow diversion as the most common. These procedures were performed safely with subsequent obliteration of most aneurysms. The potential need for retreatment of aneurysms should be considered during primary WEB treatments.
BACKGROUND: The Woven EndoBridge (WEB) device (Terumno Corp. [parent company of Microvention]) was approved by the U.S. Food and Drug Administration as the first intrasaccular device for intracranial aneurysm treatment in December 2018. Its use has become more common since then, but both trial results and postmarket experiences have raised questions about the efficacy in achieving complete aneurysm obliteration. Retreatment after WEB embolization has not been extensively discussed. OBJECTIVE: To discuss the incidence and retreatment of aneurysms after initial WEB embolization. METHODS: Retrospective review across 13 institutions identified all occurrences of WEB retreatment within neurovascular databases. Details regarding demographics, aneurysm characteristics, treatment considerations, clinical outcomes, and aneurysm occlusion were obtained and analyzed. RESULTS: Thirty aneurysms were retreated in 30 patients in a cohort of 342 WEB-treated aneurysms. The retreatment rate was 8.8%. Endovascular methods were used for 23 cases, and 7 were treated surgically. Two aneurysms presented with rehemorrhage after initial WEB embolization. Endovascular treatments included stent-assisted coiling (12), flow diversion (7), coiling (2), PulseRider (Johnson & Johnson)-assisted coiling (1), and additional WEB placement (1). Surgical treatments included primary clipping (6) and Hunterian ligation (1). There were no major complications within the study group. CONCLUSION: WEB retreatments were successfully performed by a variety of techniques, including stent-assisted coiling, clipping, and flow diversion as the most common. These procedures were performed safely with subsequent obliteration of most aneurysms. The potential need for retreatment of aneurysms should be considered during primary WEB treatments.
Authors: B Lubicz; J Klisch; J-Y Gauvrit; I Szikora; M Leonardi; T Liebig; N P Nuzzi; E Boccardi; F D Paola; M Holtmannspötter; W Weber; E Calgliari; V Sychra; B Mine; L Pierot Journal: AJNR Am J Neuroradiol Date: 2014-01-23 Impact factor: 3.825
Authors: David Fiorella; Adam Arthur; James Byrne; Laurent Pierot; Andy Molyneux; Gary Duckwiler; Thomas McCarthy; Charles Strother Journal: J Neurointerv Surg Date: 2014-07-01 Impact factor: 5.836
Authors: Christoph Kabbasch; Lukas Goertz; Eberhard Siebert; Moriz Herzberg; Jan Borggrefe; Boris Krischek; Franziska Dorn; Thomas Liebig Journal: World Neurosurg Date: 2019-06-07 Impact factor: 2.104
Authors: D Herbreteau; R Bibi; A P Narata; K Janot; C Papagiannaki; S Soize; L Pierot Journal: AJNR Am J Neuroradiol Date: 2016-08-18 Impact factor: 3.825
Authors: J-K Burkhardt; V Srinivasan; A Srivatsan; F Albuquerque; A F Ducruet; B Hendricks; B A Gross; B T Jankowitz; A J Thomas; C S Ogilvy; G A Maragkos; A Enriquez-Marulanda; R W Crowley; M R Levitt; L J Kim; C J Griessenauer; C M Schirmer; S Dalal; K Piper; M Mokin; E A Winkler; A A Abla; C McDougall; L Birnbaum; J Mascitelli; M Litao; O Tanweer; H Riina; J Johnson; S Chen; P Kan Journal: AJNR Am J Neuroradiol Date: 2020-05-28 Impact factor: 3.825
Authors: Jacob Cherian; Stephen R Chen; Ajit Puri; Kunal Vakharia; Elad Levy; Sheila Eshraghi; Brian M Howard; Frank C Tong; C Michael Cawley; Bradley Gross; Matthew D Alexander; Ramesh Grandhi; Visish M Srinivasan; Jan-Karl Burkhardt; Jeremiah N Johnson; Peter Kan Journal: Neurosurgery Date: 2021-07-15 Impact factor: 4.654